Lost Insurance Coverage for Zepbound or Wegovy? Your Options in 2026

A denial letter and a formulary change are different problems. A prior-authorization denial means the drug is on your plan but you didn't meet its criteria - BMI thresholds, documented conditions, a prior program - and can often be appealed with better documentation from your prescriber.

A formulary exclusion means your plan no longer covers the drug for weight management at all, and no appeal fixes that; you need a different route. A plan change at work or through a new year is the same as an exclusion until proven otherwise. Our guide to GLP-1s with insurance walks through reading the formulary and the appeal; the rest of this page is for when the answer is no.

Both manufacturers sell direct and both publish prices. The clearest example right now is Eli Lilly's Foundayo (orforglipron), the daily pill FDA-approved in April 2026: through LillyDirect it lists $149 a month at the 0.8 mg starting dose, $199 at 2.5 mg, $299 at 5.5 and 9 mg, and $349 at 14.5 and 17.2 mg, or $25 a month for commercially insured patients with its savings card - which can apply even when the plan itself declines to pay.

Savings cards for Zepbound and Wegovy exist too, with their own eligibility rules; we haven't verified their current terms, so check the manufacturer's page directly. Direct-pay still requires a prescription from a licensed clinician.

If you are on Medicare, the biggest change of 2026 applies to you. The Medicare GLP-1 Bridge is a CMS pilot that runs from July 1, 2026 through December 31, 2027 and charges eligible beneficiaries a flat $50 copay at the pharmacy for covered obesity drugs - the Wegovy pill and injection, the Zepbound KwikPen and Foundayo - with the copay staying at $50 as the dose rises.

Eligibility runs through clinical criteria and an approval step, and the program is explicitly temporary. Our GLP-1s after 65 page covers what we could verify and what to ask CMS or your Part D plan.

If you want to stay on the exact product you were prescribed, several online providers sell it at a cash price. At our last verification, altRx lists Zepbound at $1,249 a month and Wegovy at $1,579, wellmedr Zepbound at $1,599, and Sprout Wegovy at $1,799; ro sells the Zepbound KwikPen from $299 for the first month, then $399-449, plus a membership - and because ro bills the pen as its own line item, a plan that still covers it can pay its share.

The full ladder, with what each route includes, is in what Zepbound costs online. This is the most expensive route on the page, and the one with no change in product.

The question that worries people most is restarting from the lowest dose after months of titration. It is a clinical question, not a provider policy: a licensed clinician at the new provider reviews your current dose and history and decides whether to continue at that dose or step down, and most telehealth intake forms ask for it.

Bring your current prescription and the date of your last injection. The practical steps - timing the switch so you don't run out, what to send, what to ask - are in switching from Ozempic or another GLP-1.

What you should not do is bridge the gap with an unregulated "research peptide" bought without a prescription; here is why.